However, she advises to make patients aware of possible cataract formation, especially in light of the ever-increasing attention and publicity surrounding this drug category
Advantage : Semaglutide Regulatory and Availability# CagriSema : Novo Nordisk filed for FDA approval in 2025 based on REDEFINE results
The commercial game for positions 2 through 5 in the triple-agonist category is not "match Retatrutide's 28.7%." It is "deliver 20-24% at a materially lower price, with a better tolerability profile, or via an oral formulation that improves compliance." 5.4 The Dysesthesia Signal and What It Implies Mechanistically Retatrutide's TRIUMPH-4 readout reported dysesthesia - abnormal sensory nerve sensations including tingling, burning, or reduced sensation - at 8% on the 9 mg arm and 20.9% on the 12 mg arm
In psoriasis, this immune reaction causes skin cells to multiply too quickly, leading to thick, red patches on the skin
They can help you build a plan that supports your goals, preferences, and long-term health